文献速递白血病

CD37在急性髓系白血病中:一种新型表面靶点用于药物递送

CD37 in acute myeloid leukemia: a novel surface target for drug delivery.
PubMed 文献 · Blood Adv · 2025-01-01

研究发现造血限制性四跨膜蛋白CD37在多数原代急性髓系白血病(AML)原始细胞上表达,可作为不受亚型限制的共性治疗靶点。CD37在AML原始细胞中经动力蛋白依赖性内吞快速内化,且内化特性区别于正常血细胞。抗CD37抗体药物偶联物Debio 1562(αCD37-DM1)对AML原始细胞高度细胞毒性而不伤及正常造血干细胞,并在多种体内AML模型中改善临床结局和总生存。

要点

  • CD37在多数原代AML原始细胞上表达,可能成为不受亚型限制的AML治疗靶点。
  • CD37在AML原始细胞中经动力蛋白依赖性内吞快速内化,内化特性区别于正常血细胞。
  • αCD37-DM1对AML原始细胞高度细胞毒性而不伤及正常造血干细胞,在多种体内AML模型中改善临床结局和总生存。

核心结论

  • 以抗体药物偶联物如αCD37-DM1靶向CD37是治疗AML可行且有前景的治疗选择。

研究设计与样本

  • 研究为实验性研究,发现CD37在多数原代AML原始细胞上表达,并评估CD37内化特性及αCD37-DM1的细胞毒性和体内抗白血病效果。

主要发现

  • CD37在多数原代AML原始细胞上表达,可能成为不受亚型限制的AML治疗靶点。
  • CD37在AML原始细胞中经动力蛋白依赖性内吞快速内化,其内化特性区别于正常血细胞。
  • αCD37-DM1对AML原始细胞高度细胞毒性,但对正常造血干细胞无高度细胞毒性。
  • αCD37-DM1在多种体内AML模型中改善临床结局和总生存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) is the most common and lethal leukemia in adults. AML consists of many genetic subtypes, which limits broad applicability of targeted therapy. We discovered that the hematopoiesis-restricted tetraspanin CD37 is expressed on the majority of primary AML blasts and thus may represent a common therapeutic target for AML regardless of subtype. We demonstrate that the internalization properties of CD37 are distinct in AML blasts when compared with normal blood cells, and that CD37 rapidly accumulates inside AML blasts via dynamin-dependent endocytosis. Our work revealed that the clinically relevant anti-CD37 antibody-drug conjugate (ADC) Debio 1562 (αCD37-DM1) is highly cytotoxic to AML blasts, but not normal hematopoietic stem cells. We found that αCD37-DM1 improved clinical outcomes and overall survival in multiple in vivo models of AML. Together, these data demonstrate that targeting CD37 with an ADC such as αCD37-DM1 is a feasible and promising therapeutic option for the treatment of AML.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Jeremy E, Artiga E, Elgamal S, et al. CD37 in acute myeloid leukemia: a novel surface target for drug delivery. Blood Adv. 2025. PMID: 39348689. doi:10.1182/bloodadvances.2024013590

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。